-DOCSTART- -X- O
The -X- _ O
spectrum -X- _ O
of -X- _ O
infectious -X- _ O
diseases -X- _ O
has -X- _ O
shifted -X- _ O
in -X- _ O
the -X- _ O
past -X- _ O
50 -X- _ O
years -X- _ O
to -X- _ O
include -X- _ O
those -X- _ O
caused -X- _ O
by -X- _ O
microbes -X- _ O
that -X- _ O
cause -X- _ O
disease -X- _ O
predominantly -X- _ O
in -X- _ O
immunocompromised -X- _ O
individuals. -X- _ O
This -X- _ O
phenomenon -X- _ O
has -X- _ O
underscored -X- _ O
the -X- _ O
dependence -X- _ O
of -X- _ O
microbial -X- _ O
virulence -X- _ O
on -X- _ O
the -X- _ O
immune -X- _ O
status -X- _ O
of -X- _ O
the -X- _ O
host. -X- _ O
The -X- _ O
limited -X- _ O
efficacy -X- _ O
of -X- _ O
the -X- _ O
available -X- _ O
antimicrobial -X- _ O
armamentarium -X- _ O
in -X- _ O
immunocompromised -X- _ B-Patient
individuals -X- _ I-Patient
, -X- _ O
combined -X- _ O
with -X- _ O
increasing -X- _ O
resistance -X- _ O
to -X- _ O
these -X- _ O
agents -X- _ O
, -X- _ O
has -X- _ O
led -X- _ O
to -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
for -X- _ O
new -X- _ O
therapies -X- _ O
for -X- _ O
infectious -X- _ O
diseases. -X- _ O
Immunomodulation -X- _ B-Intervention
represents -X- _ O
a -X- _ O
novel -X- _ O
approach -X- _ O
to -X- _ O
antimicrobial -X- _ O
therapy -X- _ O
that -X- _ O
depends -X- _ O
on -X- _ O
bolstering -X- _ O
host -X- _ O
immunity -X- _ O
, -X- _ O
rather -X- _ O
than -X- _ O
direct -X- _ O
antimicrobial -X- _ O
activity. -X- _ O
Immunomodulators -X- _ O
can -X- _ O
be -X- _ O
divided -X- _ B-Outcome
into -X- _ I-Outcome
those -X- _ I-Outcome
that -X- _ I-Outcome
are -X- _ I-Outcome
specific -X- _ I-Outcome
to -X- _ I-Outcome
pathogens -X- _ I-Outcome
( -X- _ I-Outcome
pathogen- -X- _ I-Outcome
specific -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
that -X- _ I-Outcome
are -X- _ I-Outcome
not -X- _ I-Outcome
specific -X- _ I-Outcome
to -X- _ I-Outcome
pathogens -X- _ I-Outcome
( -X- _ I-Outcome
non-specific -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
However -X- _ O
, -X- _ O
to -X- _ O
date -X- _ O
only -X- _ O
a -X- _ O
few -X- _ O
immunomodulators -X- _ B-Intervention
have -X- _ O
been -X- _ O
evaluated -X- _ O
for -X- _ O
their -X- _ O
efficacy -X- _ O
as -X- _ O
antimicrobial -X- _ O
tools -X- _ O
. -X- _ O

